Edition:
United Kingdom

Illumina Inc (ILMN.OQ)

ILMN.OQ on NASDAQ Stock Exchange Global Select Market

241.31USD
18 Jan 2018
Change (% chg)

$-0.74 (-0.31%)
Prev Close
$242.05
Open
$242.24
Day's High
$243.50
Day's Low
$240.18
Volume
289,556
Avg. Vol
315,610
52-wk High
$248.81
52-wk Low
$156.51

Latest Key Developments (Source: Significant Developments)

Illumina Sees Non-GAAP Diluted EPS Attributable To Illumina Stockholders In Range Of $4.50-$4.60 For Fiscal Year 2018
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Illumina Inc ::ILLUMINA INC - SEES NON-GAAP DILUTED EPS ATTRIBUTABLE TO ILLUMINA STOCKHOLDERS IN RANGE OF $4.50 - $4.60 FOR FISCAL YEAR 2018.ILLUMINA - SEES SEES GAAP DILUTED EPS ATTRIBUTABLE TO ILLUMINA STOCKHOLDERS IN RANGE OF $4.14 - $4.24 FOR FISCAL YEAR 2018- SEC FILING.  Full Article

HTG Molecular, Illumina Agreed To Third Development Plan Under Parties' Amended & Restated Development & Supply Agreement
Wednesday, 27 Dec 2017 

Dec 27 (Reuters) - HTG Molecular Diagnostics Inc ::HTG MOLECULAR DIAGNOSTICS - ON DEC 23, CO, ILLUMINA AGREED TO THIRD DEVELOPMENT PLAN UNDER PARTIES' AMENDED & RESTATED DEVELOPMENT & SUPPLY AGREEMENT.HTG MOLECULAR DIAGNOSTICS SAYS UNDER PLAN, ILLUMINA EXPECTED TO DEVELOP & DELIVER TO CO EXECUTABLE VERSION OF CUSTOM SOFTWARE - SEC FILING.  Full Article

Luna Dna Announces $2 Mln In Seed Funding Round Included Several Individual Investors And Former Executives From Illumina
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Illumina Inc ::LUNA DNA ANNOUNCES $2 MILLION IN SEED FUNDING; ROUND INCLUDED SEVERAL INDIVIDUAL INVESTORS AND FORMER EXECUTIVES FROM ILLUMINA.  Full Article

Disney Board Elects Oracle And Illumina CEOs As Directors
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Walt Disney Co ::DISNEY BOARD ELECTS ORACLE’S SAFRA CATZ AND ILLUMINA’S FRANCIS A. DESOUZA AS DIRECTORS.WALT DISNEY CO - ELECTIONS OF CATZ AND DESOUZA ARE EFFECTIVE FEBRUARY 1, 2018.WALT DISNEY CO - ELECTION OF 2 NEW DIRECTORS: SAFRA CATZ, CEO OF ORACLE, AND FRANCIS DESOUZA, CEO OF BIOTECHNOLOGY FIRM ILLUMINA INC.  Full Article

Illumina reports Q3 GAAP earnings per share $1.11
Tuesday, 24 Oct 2017 

Oct 25 (Reuters) - Illumina Inc :Illumina reports financial results for third quarter of fiscal year 2017.Q3 non-GAAP earnings per share $1.11.Q3 GAAP earnings per share $1.11.Q3 revenue $714 million versus I/B/E/S view $692.8 million.Sees fy 2017 non-GAAP earnings per share $3.73 to $3.78.Sees fy 2017 revenue up about 13 percent.Q3 earnings per share view $0.99 -- Thomson Reuters I/B/E/S.Illumina Inc - ‍for fiscal 2017 company now projects GAAP earnings per diluted share attributable to Illumina stockholders of $5.56 to $5.61​.Fy2017 earnings per share view $3.65, revenue view $2.68 billion -- Thomson Reuters I/B/E/S.  Full Article

Illumina increases size of board from eight to nine members
Thursday, 28 Jul 2016 

Illumina Inc : Effective as of july 27, 2016, board of directors increased size of board from eight to nine members - sec filing Further company coverage: [ILMN.O] (Bengaluru Newsroom: +1-646-223-8780).  Full Article

Illumina reports Q2 adj. earnings $0.86/shr
Tuesday, 26 Jul 2016 

Illumina Inc : Illumina reports financial results for second quarter of fiscal year 2016 . Q2 non-GAAP earnings per share $0.86 . Q2 GAAP earnings per share $0.82 . Sees Q3 2016 revenue $625 million to $630 million . Q2 revenue $600 million versus I/B/E/S view $593.1 million . Sees FY 2016 non-GAAP earnings per share $3.48 to $3.58 . Sees FY 2016 revenue up about 12 percent .Q2 earnings per share view $0.73 -- Thomson Reuters I/B/E/S.  Full Article

Enzo Biochem says Enzo Life Sciences reached settlement with Illumina that included payment of $21 mln to Enzo
Thursday, 7 Jul 2016 

Enzo Biochem Inc : Co's unit, Enzo Life Sciences, has reached and finalized a settlement with Illumina that included a payment of $21 million to enzo . Settlement resolving dispute between Enzo Life Sciences and Illumina impacts only one of 11 cases originally brought by enzo .Settlement related to action brought in delaware court by Enzo alleging infringement of patent.  Full Article

Illumina received a product approval certificate for MiSeqDx instrument
Monday, 9 May 2016 

Illumina Inc :Received a product approval certificate for Miseqdx Instrument and Miseqdx universal kit with MFDS in South Korea.  Full Article

Illumina Files Patent Infringement Suit in Switzerland against Genoma SA
Thursday, 21 Apr 2016 

Illumina:Says co and unit Verinata Health, Inc. (together "Illumina"), filed a patent infringement suit against Genoma SA in the Federal Patent Court in Switzerland.Illumina is seeking all available remedies, including damages and injunctive relief. The patents asserted are European Patent (CH) 2 183 693 B1, European Patent (CH) 0 994 963 B2, European Patent (CH) 1 981 995 B1, and European Patent (CH) 2 514 842.The patents are directed to using cell-free fetal DNA for non-invasive prenatal testing (NIPT).Tranquility NIPT service uses the IONA(reg) Test sold by Premaitha Health plc. Illumina previously filed separate suits against Premaitha in the United Kingdom for sale of the IONA Test.  Full Article

BRIEF-Illumina Sees Non-GAAP Diluted EPS Attributable To Illumina Stockholders In Range Of $4.50-$4.60 For Fiscal Year 2018

* ILLUMINA INC - SEES NON-GAAP DILUTED EPS ATTRIBUTABLE TO ILLUMINA STOCKHOLDERS IN RANGE OF $4.50 - $4.60 FOR FISCAL YEAR 2018